Rivastigmine in Alzheimer disease: efficacy over two years.

  title={Rivastigmine in Alzheimer disease: efficacy over two years.},
  author={George T Grossberg and Peter Irwin and Andrew Satlin and Peter G Mesenbrink and Ren{\'e} Spiegel},
  journal={The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
  volume={12 4},
OBJECTIVE Beyond 6 to 9 months of treatment with cholinesterase inhibitors (ChE-Is), there is a notable increase in the rate of cognitive decline in Alzheimer disease (AD) patients, and there are few longer-term studies to evaluate this finding. The authors examined whether the ChE-I rivastigmine continued to be therapeutically effective after up to 2 years of treatment in 2,010 patients with probable AD. METHODS The clinical course of AD patients treated with rivastigmine was compared with a… CONTINUE READING